## **Amendments to Specification**

## Please delete lines 5 through 8 on page 1 and substitute with the following:

This application claims priority to U.S. Patent Application No. 09/513,351 (filed February 24, 2000), which, in turn, claims priority to both International Patent Application PCT/US99/26007 (filed on November 17, 1999, and published as International Publication No. WO 00/31063) and U.S. Patent Application No. 09/196,623 (filed November 20, 1998). International Patent Application PCT/US99/26007 claims priority to U.S. Patent Application No. 09/196,623. U.S. Patent Application No. 09/196,623 claims priority to U.S. Patent Application No. 09/083,670 (filed May 22, 1998), which, in turn, claims priority to U.S. Provisional Patent Application No. 60/047,570 (filed May 22, 1997). The text of each of the above-referenced applications is incorporated by reference.

Please insert the following text on a new page at the end of the application (i.e., after the claims):

## **ABSTRACT**

 $R^{4} \xrightarrow{(5)^{1}} R^{2}$   $R^{4} \xrightarrow{(5)^{1}} R^{2}$   $R^{1}$ (IA)

A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula (IA), wherein  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  are as described in the specification.